Table 3 Patient, tumour and treatment characteristics of the study population. Data are presented for patients with or without textbook outcome

Age (years)

Mean ± SD

64.5 ± 9.7

64.8 ± 9.5

63.5 ± 10.4

0.418

Sex (male)

n (%)

91 (83%)

70 (83%)

21 (81%)

0.771

BMI (kg/m²)

Mean ± SD

27.0 ± 4.9

27.0 ± 4.9

27.0 ± 5.2

0.933

ASA grade

n (%)

 ASA I–II

n (%)

37 (34%)

26 (31%)

11 (42%)

0.344

 ASA III–IV

n (%)

73 (66%)

58 (69%)

15 (58%)

CCI score

Mean ± SD

4.4 ± 1.6

4.5 ± 1.6

4.1 ± 1.4

0.24

Tumour variables

Tumour location

 Proximal third

n (%)

3/108 (3%)

2/83 (2%)

1/25 (4%)

0.514

 Middle third

n (%)

5/108 (5%)

5/83 (6%)

0/25 (0%)

 Distal third

n (%)

34/108 (31%)

28/83 (34%)

6/25 (24%)

 Gastroesophageal junction

n (%)

59/108 (55%)

42/83 (51%)

17/25 (68%)

 Other

n (%)

7/108 (6%)

6/83 (7%)

1/25 (4%)

Tumour histological type

 Adenocarcinoma

n (%)

90 (82%)

67 (80%)

23 (88%)

0.751

 Squamous cell carcinoma

n (%)

13 (12%)

11 (13%)

2 (8%)

 Other

n (%)

7 (6%)

6 (7%)

1 (4%)

cT-stage

 T0–2, n (%)

16/51 (31%)

12/41 (29%)

4/10 (40%)

0.705

 T3–4, n (%)

35/51 (69%)

29/41 (71%)

6/10 (60%)

cN-stage

 N0, n (%)

64/104 (62%)

46/79 (58%)

18/25 (72%)

0.196

 N1, n (%)

38/104 (37%)

32/79 (41%)

6/25 (24%)

 N2–3, n (%)

2/104 (2%)

1/79 (1%)

1/25 (4%)

Treatment characteristics

Neoadjuvant therapy

 None

7 (6%)

4 (5%)

3 (12%)

0.704

 Chemotherapy

70 (64%)

54 (64%)

16 (62%)

 Chemoradiotherapy

6 (5%)

5 (6%)

1 (4%)

 Other

27 (25%)

21 (25%)

6 (23%)

Surgical approach

 Open

94 (85%)

73 (87%)

21 (81%)

0.672

 Minimally invasive

3 (3%)

3 (3%)

0 (0%)

 Hybrid thoracoscopy

13 (12%)

8/83 (10%)

5 (19%)